Novo Nordisk cuts Wegovy price in South Africa for a second time

Novo Nordisk cut South African prices for its weight‑loss drug Wegovy for a second time since the product's August launch, citing fierce competition led by Eli Lilly. The repeated price reduction signals intensifying GLP‑1 pricing pressure in South Africa, with likely regional margin erosion and lower revenue per patient for Wegovy; monitor for spillover pricing dynamics in other emerging markets.

Analysis

Novo Nordisk cut South African prices for its weight‑loss drug Wegovy for a second time since the product's August launch, citing fierce competition led by Eli Lilly. The repeated price reduction signals intensifying GLP‑1 pricing pressure in South Africa, with likely regional margin erosion and lower revenue per patient for Wegovy; monitor for spillover pricing dynamics in other emerging markets.